BACKGROUND: Tyrosine kinase inhibitors (TKIs) significantly improve survival in patients with chronic myeloid leukemia in chronic phase (CML-CP). Conditional probability provides survival information in patients who have already survived for a specific period of time after treatment. METHODS: Cumulative response and survival data from 6 consecutive frontline TKI clinical trials were analyzed. Conditional probability was calculated for failure-free survival (FFS), transformation-free survival (TFS), event-free survival (EFS), and overall survival (OS) according to depth of response within 1 year of the initiation of TKIs, including complete cytogenetic response, major molecular response, and molecular response with a 4-log or 4.5-log reduction. RESULTS: A total of 483 patients with a median follow-up of 99.4 months from the initiation of treatment with TKIs were analyzed. Conditional probabilities of FFS, TFS, EFS, and OS for 1 additional year for patients alive after 12 months of therapy ranged from 92.0% to 99.1%, 98.5% to 100%, 96.2% to 99.6%, and 96.8% to 99.7%, respectively. Conditional FFS for 1 additional year did not improve with a deeper response each year. Conditional probabilities of TFS, EFS, and OS for 1 additional year were maintained at >95% during the period. CONCLUSIONS: In the era of TKIs, patients with chronic myeloid leukemia in chronic phase who survived for a certain number of years maintained excellent clinical outcomes in each age group. Cancer 2016;122:238-248.
BACKGROUND:Tyrosine kinase inhibitors (TKIs) significantly improve survival in patients with chronic myeloid leukemia in chronic phase (CML-CP). Conditional probability provides survival information in patients who have already survived for a specific period of time after treatment. METHODS: Cumulative response and survival data from 6 consecutive frontline TKI clinical trials were analyzed. Conditional probability was calculated for failure-free survival (FFS), transformation-free survival (TFS), event-free survival (EFS), and overall survival (OS) according to depth of response within 1 year of the initiation of TKIs, including complete cytogenetic response, major molecular response, and molecular response with a 4-log or 4.5-log reduction. RESULTS: A total of 483 patients with a median follow-up of 99.4 months from the initiation of treatment with TKIs were analyzed. Conditional probabilities of FFS, TFS, EFS, and OS for 1 additional year for patients alive after 12 months of therapy ranged from 92.0% to 99.1%, 98.5% to 100%, 96.2% to 99.6%, and 96.8% to 99.7%, respectively. Conditional FFS for 1 additional year did not improve with a deeper response each year. Conditional probabilities of TFS, EFS, and OS for 1 additional year were maintained at >95% during the period. CONCLUSIONS: In the era of TKIs, patients with chronic myeloid leukemia in chronic phase who survived for a certain number of years maintained excellent clinical outcomes in each age group. Cancer 2016;122:238-248.
Authors: Hagop M Kantarjian; Neil P Shah; Jorge E Cortes; Michele Baccarani; Mohan B Agarwal; María Soledad Undurraga; Jianxiang Wang; Juan Julio Kassack Ipiña; Dong-Wook Kim; Michinori Ogura; Carolina Pavlovsky; Christian Junghanss; Jorge H Milone; Franck E Nicolini; Tadeusz Robak; Jan Van Droogenbroeck; Edo Vellenga; M Brigid Bradley-Garelik; Chao Zhu; Andreas Hochhaus Journal: Blood Date: 2011-12-09 Impact factor: 22.113
Authors: Maryska L G Janssen-Heijnen; Adam Gondos; Freddie Bray; Timo Hakulinen; David H Brewster; Hermann Brenner; Jan-Willem W Coebergh Journal: J Clin Oncol Date: 2010-04-20 Impact factor: 44.544
Authors: Hagop Kantarjian; Ricardo Pasquini; Vincent Lévy; Saengsuree Jootar; Jerzy Holowiecki; Nelson Hamerschlak; Timothy Hughes; Eric Bleickardt; David Dejardin; Jorge Cortes; Neil P Shah Journal: Cancer Date: 2009-09-15 Impact factor: 6.860
Authors: Hagop M Kantarjian; Francis J Giles; Kapil N Bhalla; Javier Pinilla-Ibarz; Richard A Larson; Norbert Gattermann; Oliver G Ottmann; Andreas Hochhaus; Jerald P Radich; Giuseppe Saglio; Timothy P Hughes; Giovanni Martinelli; Dong-Wook Kim; Yaping Shou; Neil J Gallagher; Rick Blakesley; Michele Baccarani; Jorge Cortes; Philipp D le Coutre Journal: Blood Date: 2010-11-22 Impact factor: 22.113
Authors: Michele Baccarani; Michael W Deininger; Gianantonio Rosti; Andreas Hochhaus; Simona Soverini; Jane F Apperley; Francisco Cervantes; Richard E Clark; Jorge E Cortes; François Guilhot; Henrik Hjorth-Hansen; Timothy P Hughes; Hagop M Kantarjian; Dong-Wook Kim; Richard A Larson; Jeffrey H Lipton; François-Xavier Mahon; Giovanni Martinelli; Jiri Mayer; Martin C Müller; Dietger Niederwieser; Fabrizio Pane; Jerald P Radich; Philippe Rousselot; Giuseppe Saglio; Susanne Saußele; Charles Schiffer; Richard Silver; Bengt Simonsson; Juan-Luis Steegmann; John M Goldman; Rüdiger Hehlmann Journal: Blood Date: 2013-06-26 Impact factor: 22.113
Authors: Koji Sasaki; Hagop M Kantarjian; Susan O'Brien; Farhad Ravandi; Marina Konopleva; Gautam Borthakur; Guillermo Garcia-Manero; William G Wierda; Naval Daver; Alessandra Ferrajoli; Koichi Takahashi; Preetesh Jain; Mary Beth Rios; Sherry A Pierce; Elias J Jabbour; Jorge E Cortes Journal: Int J Hematol Date: 2019-03-04 Impact factor: 2.490
Authors: Ghayas C Issa; Hagop M Kantarjian; Graciela Nogueras Gonzalez; Gautam Borthakur; Guilin Tang; William Wierda; Koji Sasaki; Nicholas J Short; Farhad Ravandi; Tapan Kadia; Keyur Patel; Raja Luthra; Alessandra Ferrajoli; Guillermo Garcia-Manero; Mary Beth Rios; Sara Dellasala; Elias Jabbour; Jorge E Cortes Journal: Blood Date: 2017-08-23 Impact factor: 22.113
Authors: Paul B Koller; Hagop M Kantarjian; Graciela M Nogueras-Gonzalez; Elias Jabbour; Srdan Verstovsek; Gautam Borthakur; Zeev Estrov; William G Wierda; Guillermo Garcia-Manero; Alessandra Ferrajoli; Farhad Ravandi; Susan M O'Brien; Jorge E Cortes Journal: Cancer Date: 2016-10-20 Impact factor: 6.860
Authors: Eric J Chow; David R Doody; Jennifer J Wilkes; Laura K Becker; Shasank Chennupati; Pamela E Morin; Lena E Winestone; Henry J Henk; Gary H Lyman Journal: Leuk Lymphoma Date: 2020-12-07